Factor VII Inhibitor Evaluation, Plasma
Use
Detection and quantitation of inhibitor to coagulation factor VII. This test is utilized to identify specific inhibitors impacting the coagulation factor VII, which can arise due to congenital deficiencies or occur spontaneously in patients. It provides crucial information for managing bleeding disorders, especially in individuals who have undergone factor replacement therapy or present specific inhibitors.
Special Instructions
Not provided.
Limitations
This test is not useful for the detection of a lupus-like circulating anticoagulant inhibitor, a nonspecific circulating anticoagulant, or other inhibitors that are not specific for coagulation factors. False-positive results may occasionally occur due to potent lupus-like anticoagulants.
New York Approved
Methodology
Other
Biomarkers
Coagulation Factor VII
Analyte
LOINC Codes
- 90225-4 - Fact VII Act + Inhib Pnl PPP
- 3198-9 - Fact VII Act/Nor PPP
- 69049-5 - Coagulation specialist review
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
3 mL in 3 plastic vials, each containing 1 mL
Minimum Volume
2 plastic vials, each containing 1 mL
Container
Light-blue top (3.2% sodium citrate); Submission: Polypropylene plastic vials
Collection Instructions
Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again. Aliquot plasma (1-2 mL per aliquot) into 3 separate plastic vials leaving 0.25 mL in the bottom of centrifuged vial. Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or, ideally, -40 degrees C or below.
Patient Preparation
Fasting for 8 hours preferred but not required; ensure the patient is not receiving Coumadin or heparin therapy.
Storage Instructions
Freeze plasma at -20 degrees C or ideally, -40 degrees C or below.
Causes for Rejection
Reject due to gross hemolysis, gross lipemia, or gross icterus.
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |